The phase 3 clinical trial is a prospective, double-blind, randomized, placebo and midazolam-controlled multicenter study, according to the report. During phase 2 clinical trials, Remimazolam was found to have a faster onset of sedation and faster patient recovery in comparison to midazolam.
The phase 3 clinical trial will include 460 patients undergoing diagnostic and therapeutic colonoscopy.
More articles on gastroenterology:
Boston Scientific CEO says medical device tax hinders industry
18 statistics on gastroenterologist habits & burnout
6 gastroenterologists making headlines – March 27, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.